AbbVie Inc. (ABBV): A Bull Case Theory
We came across a bullish thesis on AbbVie Inc. on Dividend Talks’s Substack. In this article, we will summarize the bulls’ thesis on ABBV.
Abbvie Inc. (ABBV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Zevenbergen Capital Investments Nancy Zevenbergen | 1,923 | $356,947 | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $69.00 | 1,550 | $106,950.00 | 17,644 | 2020-03-20 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-20 | Filing | |
| $67.50 | 800 | $54,000.00 | 16,094 | 2020-03-20 | Filing | |
| $68.18 | 2,200 | $150,004.80 | 15,294 | 2020-03-18 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $210.54 | 33,132 | $6,975,611.28 | 53,234 | 2025-03-31 | Filing | |
| $209.49 | 25,700 | $5,383,893.00 | 86,366 | 2025-03-31 | Filing | |
| $212.34 | 17,644 | $3,746,526.96 | 11,577 | 2025-03-14 | Filing | |
| $210.53 | 6,168 | $1,298,549.04 | 388,929 | 2025-03-03 | Filing | |
| $205.11 | 92,460 | $18,964,470.60 | 395,097 | 2025-02-28 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,332,054 | $804,115,863 | 1.19% | |
| 2. | 1,922,679 | $356,887,678 | 0.4% | |
| 3. | 1,048,600 | $194,588,702 | 0.91% | |
| 4. | 644,425 | $119,618,162 | 2.11% | |
| 5. | 554,650 | $104,984,292 | 0.17% |
News See All
Morgan Stanley Maintained an Overweight Rating on AbbVie (ABBV)
AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks.
10 High Growth Dividend Paying Stocks to Buy
In 2024, macroeconomic uncertainty, election year volatility, and weakened consumer confidence led many corporations to adopt a more cautious approach, resulting in subdued dividend growth.
AbbVie to Acquire Capstan Therapeutics for $2.1B, Boosting Autoimmune Pipeline
AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts.
13 Most Undervalued Large Cap Stocks to Buy According to Analysts
On July 3, Ben Preston, Portfolio Manager at Orbis Investments, appeared on CNBC to suggest that investors look past the constant political headlines and market volatility and find undervalued global ...
AbbVie's Elahere Market Expected to Skyrocket to $6B by 2034 in Ovarian Cancer Treatment
AbbVie Inc. (NYSE:ABBV) is one of the undervalued S&P 500 stocks to buy according to hedge funds.
10 Undervalued S&P 500 Stocks to Buy According to Hedge Funds
On June 24, Paul Hickey, Bespoke Investment Group co-founder, joined 'Squawk Box' on CNBC to suggest that periods of widespread fear often present good buying opportunities.
AbbVie (ABBV) Reports Positive Migraine Drug Results in Phase 3 Trial
AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the company published its Phase 3 TEMPLE study results, which were positive.
Is AbbVie the Best Dividend Stock in Big Pharma Today?
The company holds the title of a Dividend King, having raised its dividend for 52 straight years.
10 Undervalued Blue Chip Stocks Analysts Recommend for Smart Investing
Blue-chip stocks are great assets for investors looking for opportunities to grow their capital in the long term. Some call them steady oaks in the forest of finance.
Billionaire Hedge Funds
